1,018 results on '"Witzenrath, Martin"'
Search Results
2. Converting PROMIS®-29 v2.0 profile data to SF-36 physical and mental component summary scores in patients with cardiovascular disorders
3. Clinically used broad-spectrum antibiotics compromise inflammatory monocyte-dependent antibacterial defense in the lung
4. Comparison of clinical outcomes in hospitalized patients with COVID-19 or non-COVID-19 community-acquired pneumonia in a prospective observational cohort study
5. Validation of risk scores for prediction of severe pneumonia in kidney transplant recipients hospitalized with community-acquired pneumonia
6. Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP)
7. Pathogen spectrum of community acquired pneumonia in people living with HIV (PLWH) in the German CAPNETZ-Cohort
8. RSV vaccination strategies for high-risk patients 2023: a collaborative position paper by leading German medical societies and organizations
9. Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort
10. Neural network-assisted humanisation of COVID-19 hamster transcriptomic data reveals matching severity states in human disease
11. Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial
12. Genetic Regulation of Cytokine Response in Patients with Acute Community-acquired Pneumonia
13. The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation
14. Single-cell-resolved interspecies comparison shows a shared inflammatory axis and a dominant neutrophil-endothelial program in severe COVID-19
15. Ethical and coordinative challenges in setting up a national cohort study during the COVID-19 pandemic in Germany
16. The unremarkable alveolar epithelial glycocalyx: a thorium dioxide-based electron microscopic comparison after heparinase or pneumolysin treatment
17. Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses
18. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01
19. Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters
20. Cationic LNP-formulated mRNA expressing Tie2-agonist in the lung endothelium prevents pulmonary vascular leakage
21. Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial
22. Mobilisation practices during the SARS-CoV-2 pandemic: A retrospective analysis (MobiCOVID)
23. Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study
24. Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer – A multicenter observational analysis
25. Resurgence of common respiratory viruses in patients with community-acquired pneumonia (CAP)—A prospective multicenter study
26. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics
27. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
28. Selective adipocyte loss of Angiopoietin-2 prompts female-specific obesity and metabolic syndrome
29. Functional limitations 12 months after SARS-CoV-2 infection correlate with initial disease severity: An observational study of cardiopulmonary exercise capacity testing in COVID-19 convalescents
30. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study
31. Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment – A multicenter analysis
32. Highly multiplexed immune repertoire sequencing links multiple lymphocyte classes with severity of response to COVID-19
33. Early post-discharge mortality in CAP: frequency, risk factors and a prediction tool
34. Adjunctive therapy with the Tie2 agonist Vasculotide reduces pulmonary permeability in Streptococcus pneumoniae infected and mechanically ventilated mice
35. Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group
36. Mobilisation of critically ill patients receiving norepinephrine: a retrospective cohort study
37. Integration von Bestandsdaten aus Kohorten- und Registerstudien in ein existierendes Forschungsnetzwerk: Nationales Pandemie Kohorten Netz (NAPKON).
38. A new phenotype of patients with post-COVID-19 condition is characterised by a pattern of complex ventilatory dysfunction, neuromuscular disturbance and fatigue symptoms.
39. Altered fibrin clot structure and dysregulated fibrinolysis contribute to thrombosis risk in severe COVID-19
40. Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months
41. Role of the complement system in Long COVID
42. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01
43. Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids
44. A time-resolved proteomic and prognostic map of COVID-19
45. Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19
46. CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity
47. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19
48. Pneumolysin induces platelet destruction, not platelet activation, which can be prevented by immunoglobulin preparations in vitro
49. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
50. VT20 method for Chartis assessment of collateral ventilation with flexible bronchoscopy under procedural sedation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.